½ÃÀ庸°í¼­
»óǰÄÚµå
1591993

¼¼°èÀÇ Ã¼¿Ü Æó ¸ðµ¨ ½ÃÀå : À¯Çüº°, ¿ëµµº° ¿¹Ãø(2025-2030³â)

In Vitro Lung Model Market by Type (2D Models, 3D Models), Application (3D Model Development, Drug Discovery & Toxicology, Physiological Research) - Global Forecast 2025-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: 360iResearch | ÆäÀÌÁö Á¤º¸: ¿µ¹® 185 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

ü¿Ü Æó ¸ðµ¨ ½ÃÀåÀº 2023³â¿¡ 5¾ï 9,159¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í, 2024³â¿¡´Â 6¾ï 8,938¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, CAGR 16.94%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 17¾ï 7,017¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

½ÃÀå ¼¼ºÐÈ­´Â º¸´Ù ±¤¹üÀ§ÇÑ ¹ÙÀÌ¿À ÀǾàǰ ¹× ÇコÄÉ¾î ¿¬±¸ ¾÷°è Áß¿¡¼­ Æ´»õÀ̸鼭 È®´ëµÇ´Â ºÎ¹®ÀÔ´Ï´Ù. ÀÌ ¸ðµ¨Àº Àΰ£ÀÇ Æó ±â´ÉÀ» ¼¼Æ÷ ¼öÁØ¿¡¼­ ÀçÇöÇÏ´Â Àΰø ½Ã½ºÅÛÀÌ¸ç ¾à¹°, µ¶¼º ½ÃÇè, Áúº´ ¸ðµ¨¸µÀ»À§ÇÑ ±ÍÁßÇÑ µµ±¸¸¦ Á¦°øÇÕ´Ï´Ù. ü¿Ü Æó ¸ðµ¨ÀÇ Çʿ伺Àº Á¦¾à Á¶»ç ¹æ¹ýÀ» °¡¼ÓÈ­ÇÏ°í µ¿¹° ½ÇÇè¿¡ ´ëÇÑ ÀÇÁ¸µµ¸¦ ÁÙÀ̰í Àΰ£ÀÇ »ý¸®Àû ¹ÝÀÀÀ» ´õ Àß ¸ð¹æÇÔÀ¸·Î½á ¿¬±¸ °á°úÀÇ Á¤È®¼º°ú Àû¿ë °¡´É¼ºÀ» ³ôÀÏ ¼ö Àֱ⠶§¹®ÀÔ´Ï´Ù. ÀÀ¿ë ¹üÀ§´Â ÀǾàǰ °³¹ß, ¸ÂÃãÇü ÀÇ·á, ¾ÈÀü ¾à¸®ÇÐ ¹× ÃÖÁ¾ »ç¿ëÀÚ´Â ÁÖ·Î Á¦¾à ȸ»ç, ¿¬±¸ ±â°ü, CRO µîÀÔ´Ï´Ù.

ÁÖ¿ä ½ÃÀå Åë°è
±âÁسâ(2023) 5¾ï 9,159¸¸ ´Þ·¯
¿¹Ãø³â(2024) 6¾ï 8,938¸¸ ´Þ·¯
¿¹Ãø³â(2030) 17¾ï 7,017¸¸ ´Þ·¯
CAGR(%) 16.94%

½ÃÀå ¼ºÀå¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ÁÖ¿ä ¿äÀÎÀ¸·Î´Â õ½Ä°ú COPD¿Í °°Àº È£Èí±â ÁúȯÀÇ À¯º´·ü »ó½Â, Á¶Á÷ °øÇÐÀÇ Áøº¸, µ¿¹° ½ÇÇè¿¡ ´ëÇÑ À±¸®Àû ¿ì·Á Áõ°¡ µîÀÌ ÀÖ½À´Ï´Ù. ¶Ç´Â Àå±â ¿ÂĨ ±â¼ú°ú °°Àº ºÐ¾ß¿¡¼­ 3D ¹ÙÀÌ¿À ÇÁ¸°ÆÃ ¹× °í±Þ »ýü Àç·á °ú °°Àº ±â¼ú Çõ½Å¿¡ °ßÀεǾî Àΰ£ÀÇ Æó¸¦ Ãæ½ÇÈ÷ ½Ã¹Ä·¹À̼ÇÇÒ ±âȸ°¡ ´Ã°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¸ðµ¨ÀÇ ÃÖÀû »ç¿ëÀ» ¾ïÁ¦ÇÒ ¼ö ÀÖ´Â °úÁ¦µµ ³²¾Æ ÀÖ½À´Ï´Ù.

µ¥ÀÌÅÍ ºÐ¼®ÀÇ Á¤È®¼ºÀ» ³ôÀ̱â À§ÇÑ ÀΰøÁö´É°ú ü¿Ü Æó ¸ðµ¨ÀÇ ÅëÇÕ, Àü½Å ÅëÂû·ÂÀ» Á¦°øÇÏ´Â ´ÙÀå±â ¸ðµ¨ °³¹ß, ü³» ȯ°æÀ» º¸´Ù Á¤È®ÇÏ°Ô ½Ã¹Ä·¹À̼ÇÇϱâ À§ÇÑ ¸¶ÀÌÅ©·ÎÇ÷çÀ̵ñ½º °øÇÐÀÇ È°¿ë µî Çõ½ÅÀûÀÎ ¿¬±¸ ºÐ¾ßÀÇ °³Ã´ÀÌ ÁøÇàµÇ°í ÀÖ½À´Ï´Ù., ±â¼ú Áøº¸ ¹× °øµ¿ ¿¬±¸ÀÇ ¿µÇâÀÌ Å®´Ï´Ù. »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Ȱ¿ëÇϱâ À§ÇØ ÀÌÇØ °ü°èÀÚ´Â ºñ¿ë È¿À²¼º Çâ»ó, ¸ðµ¨ Á¤È®¼º Çâ»ó, ±â¼ú ±â¾÷°úÀÇ Àü·«Àû ÆÄÆ®³Ê½Ê ±¸Ãà¿¡ ÁÖ·ÂÇÏ¿© ÇöÇà ü¿Ü ±â¼ú·Î ´Þ¼ºÇÒ ¼ö ÀÖ´Â °ÍÀÇ ÇѰ踦 ³ÐÇô¾ß ÇÕ´Ï´Ù.

½ÃÀå ¿ªÇÐ: ½Å¼ÓÇÏ°Ô ÁøÈ­Çϴ ü¿Ü Æó ¸ðµ¨ ½ÃÀåÀÇ ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ® °ø°³

ü¿Ü Æó ¸ðµ¨ ½ÃÀåÀº ¼ö¿ä ¹× °ø±ÞÀÇ ¿ªµ¿ÀûÀÎ »óÈ£ÀÛ¿ë¿¡ ÀÇÇØ º¯¸ð¸¦ ÀÌ·ç°í ÀÖ½À´Ï´Ù. »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ ȹµæÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ µ¿ÇâÀ» Á¾ÇÕÀûÀ¸·Î ÆÄ¾ÇÇÔÀ¸·Î½á ±â¾÷Àº Á¤Ä¡Àû, Áö¸®Àû, ±â¼úÀû, »çȸÀû, °æÁ¦Àû ¿µ¿ª¿¡ °ÉÄ£ ´Ù¾çÇÑ ¸®½ºÅ©¸¦ °æ°¨ÇÒ ¼ö ÀÖÀ» »Ó¸¸ ¾Æ´Ï¶ó, ¼ÒºñÀÚ Çൿ°ú ±×°ÍÀÌ Á¦Á¶ ºñ¿ë ¶Ç´Â ±¸¸Å µ¿Çâ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ»º¸´Ù ¸íÈ®ÇÏ°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • µ¿¹°½ÇÇèÀ» ´ëüÇÏ´Â À±¸®Àû ¼ö¹ý¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡
    • â¾à °³¹ß Áõ°¡
    • Áúº´ ¿¬±¸¿¡¼­ ü¿Ü Æó ¸ðµ¨ÀÇ ±¤¹üÀ§ÇÑ »ç¿ë
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ü¿Ü Æó ¸ðµ¨ÀÇ °³¹ß°ú À¯Áö¿¡ µå´Â °íºñ¿ë
  • ½ÃÀå ±âȸ
    • ¸ÂÃãÇü ÀÇ·á¿¡ÀÇ °æ»ç
    • ´Ù¾çÇÑ ¹°ÁúÀÇ µ¶¼º ½ÃÇè¿¡ÀÇ ÀÌ¿ë
  • ½ÃÀåÀÇ °úÁ¦
    • ü¿Ü Æó ¸ðµ¨¿¡ µû¸¥ »ý¸®Àû º¹À⼺

Porter's Five Forces: ü¿Ü Æó ¸ðµ¨ ½ÃÀåÀ» Ž»öÇÏ´Â Àü·« µµ±¸

Porter's Five Forces ÇÁ·¹ÀÓ ¿öÅ©´Â ½ÃÀå »óȲ°æÀï ±¸µµ¸¦ ÀÌÇØÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ±â¹ýÀ» Á¦°øÇÕ´Ï´Ù. ±â¾÷ÀÌ ½ÃÀå ³» ¼¼·Âµµ¸¦ Æò°¡ÇÏ°í ½Å±Ô »ç¾÷ÀÇ ¼öÀͼºÀ» ÆÇ´ÜÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ´õ °­ÀÎÇÑ ½ÃÀå¿¡¼­ Æ÷Áö¼Å´×À» º¸Àå ÇÒ ¼ö ÀÖ½À´Ï´Ù.

PESTLE ºÐ¼® : ü¿Ü Æó ¸ðµ¨ ½ÃÀå¿¡¼­ ¿ÜºÎ ¿µÇâÀ» ÆÄ¾Ç

¿ÜºÎ °Å½Ã ȯ°æ ¿äÀÎÀº ü¿Ü Æó ¸ðµ¨ ½ÃÀåÀÇ ¼º°ú ¿ªÇÐÀ» Çü¼ºÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ»ÇÕ´Ï´Ù. ¿µÇâÀ» Ž»öÇÏ´Â µ¥ ÇÊ¿äÇÑ Á¤º¸¸¦ Á¦°øÇÕ´Ï´Ù. PESTLE ¿äÀÎÀ» Á¶»çÇÏ¸é ±â¾÷Àº ÀáÀçÀûÀÎ À§Çè°ú ±âȸ¸¦ ´õ Àß ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. À» ¿¹ÃøÇÏ´Â Àû±ØÀûÀÎ ÀÇ»ç °áÁ¤À» ÇÒ Áغñ°¡µÇ¾î ÀÖ½À´Ï´Ù.

½ÃÀå Á¡À¯À² ºÐ¼® : ü¿Ü Æó ¸ðµ¨ ½ÃÀå¿¡¼­ °æÀï ±¸µµ ÆÄ¾Ç

ü¿Ü Æó ¸ðµ¨ ½ÃÀåÀÇ »ó¼¼ÇÑ ½ÃÀå Á¡À¯À² ºÐ¼®À» ÅëÇØ °ø±Þ¾÷üÀÇ ¼º°ú¸¦ Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. °ø°³ ÀÌ ºÐ¼®À» ÅëÇØ ½ÃÀå ÁýÁß, ´ÜÆíÈ­, ÅëÇÕ µ¿ÇâÀ» ¹àÇô³»°í º¥´õ´Â °æÀïÀÌ Ä¡¿­ÇØÁö¸é¼­ ÀÚ»çÀÇ ÁöÀ§¸¦ ³ôÀÌ´Â Àü·«Àû ÀÇ»ç°áÁ¤À» Çϱâ À§ÇØ ÇÊ¿äÇÑ Áö°ß ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º : ü¿Ü Æó ¸ðµ¨ ½ÃÀå¿¡¼­ °ø±Þ¾÷üÀÇ ¼º´É Æò°¡

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º´Â ü¿Ü Æó ¸ðµ¨ ½ÃÀå¿¡¼­ º¥´õ¸¦ Æò°¡ÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ³× °¡Áö »çºÐ¸éÀ» ÅëÇØ º¥´õ¸¦ ¸íÈ®Çϰí Á¤È®ÇÏ°Ô ºÐÇÒÇϰí Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê ¹× ¼Ö·ç¼ÇÀ» ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù.

Àü·« ºÐ¼® ¹× ±ÇÀå : ü¿Ü Æó ¸ðµ¨ ½ÃÀå¿¡¼­ ¼º°ø¿¡ ´ëÇÑ °æ·Î¸¦ ±×¸³´Ï´Ù.

ü¿Ü Æó ¸ðµ¨ ½ÃÀåÀÇ Àü·« ºÐ¼®Àº ¼¼°è ½ÃÀå¿¡¼­ÀÇ ÇÁ·¹Á𽺠°­È­¸¦ ¸ñÇ¥·Î ÇÏ´Â ±â¾÷¿¡ ÇʼöÀûÀÎ ¿ä¼ÒÀÔ´Ï´Ù. ÀÌ Á¢±Ù¹ýÀ» ÅëÇØ °æÀï ±¸µµ¿¡¼­ °úÁ¦¸¦ ±Øº¹ÇÏ°í »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Ȱ¿ëÇÏ¿© Àå±âÀûÀÎ ¼º°øÀ» °ÅµÑ ¼ö ÀÖ´Â ½Ã½ºÅÛÀ» ±¸ÃàÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­´Â ÁÖ¿ä °ü½É ºÐ¾ß¸¦ Æ÷°ýÇÏ´Â ½ÃÀåÀÇ Á¾ÇÕÀûÀÎ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

1. ½ÃÀå ħÅõ: ÇöÀç ½ÃÀå ȯ°æÀÇ »ó¼¼ÇÑ °ËÅä, ÁÖ¿ä ±â¾÷ÀÇ ±¤¹üÀ§ÇÑ µ¥ÀÌÅÍ, ½ÃÀå µµ´Þ¹üÀ§ ¹× Àü¹ÝÀûÀÎ ¿µÇâ·Â Æò°¡.

2. ½ÃÀå °³Ã´µµ: ½ÅÈï ½ÃÀåÀÇ ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇÏ°í ±âÁ¸ ºÐ¾ßÀÇ È®Àå °¡´É¼ºÀ» Æò°¡ÇÏ¸ç ¹Ì·¡ ¼ºÀåÀ» À§ÇÑ Àü·«Àû ·Îµå¸ÊÀ» Á¦°øÇÕ´Ï´Ù.

3. ½ÃÀå ´Ù¾çÈ­: ÃÖ±Ù Á¦Ç° Ãâ½Ã, ¹Ì°³Ã´ Áö¿ª, ¾÷°èÀÇ ÁÖ¿ä Áøº¸, ½ÃÀåÀ» Çü¼ºÇÏ´Â Àü·«Àû ÅõÀÚ¸¦ ºÐ¼®ÇÕ´Ï´Ù.

4. °æÀï Æò°¡ ¹× Á¤º¸ : °æÀï ±¸µµ¸¦ öÀúÈ÷ ºÐ¼®ÇÏ¿© ½ÃÀå Á¡À¯À², »ç¾÷ Àü·«, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÀÎÁõ, ±ÔÁ¦ ´ç±¹ ½ÂÀÎ, ƯÇã µ¿Çâ, ÁÖ¿ä ±â¾÷ÀÇ ±â¼ú Áøº¸ µîÀ» °ËÁõÇÕ´Ï´Ù.

5. Á¦Ç° °³¹ß ¹× Çõ½Å : ¹Ì·¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÃÖ÷´Ü ±â¼ú, R&D Ȱµ¿, Á¦Ç° Çõ½ÅÀ» °­Á¶ÇÕ´Ï´Ù.

¶ÇÇÑ ÀÌÇØ°ü°èÀÚ°¡ ÃæºÐÇÑ Á¤º¸¸¦ ¾ò°í ÀÇ»ç°áÁ¤À» ÇÒ ¼ö ÀÖµµ·Ï Áß¿äÇÑ Áú¹®¿¡ ´ë´äÇϰí ÀÖ½À´Ï´Ù.

1. ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÇâÈÄ ¼ºÀå ¿¹ÃøÀº?

2. ÃÖ°íÀÇ ÅõÀÚ ±âȸ¸¦ Á¦°øÇÏ´Â Á¦Ç°, ºÎ¹® ¹× Áö¿ªÀº ¾îµðÀԴϱî?

3. ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ±â¼ú µ¿Çâ°ú ±ÔÁ¦ÀÇ ¿µÇâÀº?

4. ÁÖ¿ä º¥´õÀÇ ½ÃÀå Á¡À¯À²°ú °æÀï Æ÷Áö¼ÇÀº?

5. º¥´õ ½ÃÀå ÁøÀÔ¡¤Ã¶¼ö Àü·«ÀÇ ¿øµ¿·ÂÀÌ µÇ´Â ¼öÀÍ¿ø°ú Àü·«Àû ±âȸ´Â ¹«¾ùÀΰ¡?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå °³¿ä

Á¦5Àå ½ÃÀå ÀλçÀÌÆ®

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
      • µ¿¹°½ÇÇèÀ» ´ëüÇÏ´Â À±¸®ÀûÀÎ ¹æ¹ý¿¡ ´ëÇÑ ¼ö¿ä°¡ ³ô¾ÆÁø´Ù
      • ÀǾàǰÀÇ ¹ß°ß°ú °³¹ß Áõ°¡
      • Áúȯ Á¶»ç¿¡ À־ÀÇ Ã¼¿Ü Æó ¸ðµ¨ÀÇ ±¤¹üÀ§ÇÑ ÀÌ¿ë
    • ¾ïÁ¦¿äÀÎ
      • ü¿ÜÆó ¸ðµ¨ÀÇ °³¹ß°ú À¯Áö¿¡ µå´Â ºñ¿ëÀÌ ³ô´Ù
    • ±âȸ
      • ¸ÂÃãÇü ÀÇ·á¿¡ÀÇ Á¢±Ù¿¡ÀÇ °æÇâ
      • °¢Á¾ ¹°ÁúÀÇ µ¶¼º ½ÃÇè¿¡ÀÇ ÀÌ¿ë
    • °úÁ¦
      • ü¿Ü Æó ¸ðµ¨°ú °ü·ÃµÈ »ý¸®Àû º¹À⼺
  • ½ÃÀå ¼¼ºÐÈ­ ºÐ¼®
  • Porter's Five Forces ºÐ¼®
  • PESTEL ºÐ¼®
    • Á¤Ä¡Àû
    • °æÁ¦
    • »ç±³
    • ±â¼úÀû
    • ¹ý·ü»ó
    • ȯ°æ

Á¦6Àå ü¿ÜÆó ¸ðµ¨ ½ÃÀå : À¯Çüº°

  • 2D ¸ðµ¨
  • 3D ¸ðµ¨

Á¦7Àå ü¿ÜÆó ¸ðµ¨ ½ÃÀå : ¿ëµµº°

  • 3D ¸ðµ¨ °³¹ß
  • â¾à°ú µ¶¼ºÇÐ
  • »ý¸®ÇÐÀû Á¶»ç
  • Áٱ⼼Æ÷ ¿¬±¸¿Í Àç»ýÀÇ·á

Á¦8Àå ¾Æ¸Þ¸®Ä«ÀÇ Ã¼¿ÜÆó ¸ðµ¨ ½ÃÀå

  • ¾Æ¸£ÇîÆ¼³ª
  • ºê¶óÁú
  • ij³ª´Ù
  • ¸ß½ÃÄÚ
  • ¹Ì±¹

Á¦9Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ Ã¼¿ÜÆó ¸ðµ¨ ½ÃÀå

  • È£ÁÖ
  • Áß±¹
  • Àεµ
  • Àεµ³×½Ã¾Æ
  • ÀϺ»
  • ¸»·¹À̽þÆ
  • Çʸ®ÇÉ
  • ½Ì°¡Æ÷¸£
  • Çѱ¹
  • ´ë¸¸
  • ű¹
  • º£Æ®³²

Á¦10Àå À¯·´¡¤Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ Ã¼¿ÜÆó ¸ðµ¨ ½ÃÀå

  • µ§¸¶Å©
  • ÀÌÁýÆ®
  • Çɶõµå
  • ÇÁ¶û½º
  • µ¶ÀÏ
  • À̽º¶ó¿¤
  • ÀÌÅ»¸®¾Æ
  • ³×´ú¶õµå
  • ³ªÀÌÁö¸®¾Æ
  • ³ë¸£¿þÀÌ
  • Æú¶õµå
  • īŸ¸£
  • ·¯½Ã¾Æ
  • »ç¿ìµð¾Æ¶óºñ¾Æ
  • ³²¾ÆÇÁ¸®Ä«
  • ½ºÆäÀÎ
  • ½º¿þµ§
  • ½ºÀ§½º
  • ÅÍŰ
  • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
  • ¿µ±¹

Á¦11Àå °æÀï ±¸µµ

  • ½ÃÀå Á¡À¯À² ºÐ¼® 2023
  • FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º, 2023
  • °æÀï ½Ã³ª¸®¿À ºÐ¼®
  • Àü·« ºÐ¼®°ú Á¦¾È

±â¾÷ ¸ñ·Ï

  • AlveoliX AG
  • Brainlab AG
  • Cn Bio Innovations Limited
  • Emulate, Inc.
  • Epithelix Sarl
  • Hologic, Inc.
  • Horizon Discovery Group plc
  • Insphero AG
  • Lonza Group AG
  • Mattek Corporation by Bico Group
  • McKesson Corporation
  • Merck KGaA
  • MICA Information Systems, Inc.
  • Mimetas BV
  • PromoCell GmbH
  • STEMCELL Technologies Inc.
  • Thermo Fisher Scientific Inc
  • Tissuse GmbH
  • Varian Medical Systems, Inc
JHS 24.11.26

The In Vitro Lung Model Market was valued at USD 591.59 million in 2023, expected to reach USD 689.38 million in 2024, and is projected to grow at a CAGR of 16.94%, to USD 1,770.17 million by 2030.

The In Vitro Lung Model market represents a niche yet expanding segment within the broader biopharmaceutical and healthcare research industry. These models are engineered systems that replicate human lung function at a cellular level, providing a valuable tool for drug discovery, toxicity testing, and disease modeling. The necessity for in vitro lung models arises from their potential to expedite pharmaceutical research processes, reduce reliance on animal testing, and better mimic human physiological responses, thereby enhancing the accuracy and applicability of research findings. Applications extend across drug development, personalized medicine, and safety pharmacology, with end-users primarily including pharmaceutical companies, research institutions, and CROs.

KEY MARKET STATISTICS
Base Year [2023] USD 591.59 million
Estimated Year [2024] USD 689.38 million
Forecast Year [2030] USD 1,770.17 million
CAGR (%) 16.94%

Key factors influencing market growth include the rising prevalence of respiratory diseases like asthma and COPD, advancements in tissue engineering, and growing ethical concerns over animal testing. There are notable opportunities in segments such as personalized medicine and organ-on-chip technology, driven by innovations like 3D bioprinting and advanced biomaterials that increasingly simulate human lungs with high fidelity. However, challenges remain, particularly in standardization of protocols, high costs, and limitations in accurately replicating all facets of human lung physiology which could restrain optimal use of these models.

Innovative research areas ripe for exploration include the integration of artificial intelligence with in vitro lung models to enhance data analysis accuracy, development of multi-organ models that provide systemic insights, and the utilization of microfluidics to simulate in vivo environments more accurately. The market leans towards being innovation-driven with a moderate-to-high degree of competition, largely influenced by technological advancements and collaborations. To capitalize on emerging opportunities, stakeholders must focus on increasing cost-effectiveness, improving model accuracy, and forging strategic partnerships with technology firms to push the boundaries of what's achievable with current in vitro technologies.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving In Vitro Lung Model Market

The In Vitro Lung Model Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing demand for ethical alternatives to animal testing
    • Increase in drug discovery and development
    • Extensive use of in-viro lung model in disease research
  • Market Restraints
    • High cost of development and maintainence of in-vitro lung model
  • Market Opportunities
    • Inclination toward personalized medicine approach
    • Utilization for toxicity testing of various substances
  • Market Challenges
    • Physiological complexity associated with in-vitro lung model

Porter's Five Forces: A Strategic Tool for Navigating the In Vitro Lung Model Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the In Vitro Lung Model Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the In Vitro Lung Model Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the In Vitro Lung Model Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the In Vitro Lung Model Market

A detailed market share analysis in the In Vitro Lung Model Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the In Vitro Lung Model Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the In Vitro Lung Model Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the In Vitro Lung Model Market

A strategic analysis of the In Vitro Lung Model Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the In Vitro Lung Model Market, highlighting leading vendors and their innovative profiles. These include AlveoliX AG, Brainlab AG, Cn Bio Innovations Limited, Emulate, Inc., Epithelix Sarl, Hologic, Inc., Horizon Discovery Group plc, Insphero AG, Lonza Group AG, Mattek Corporation by Bico Group, McKesson Corporation, Merck KGaA, MICA Information Systems, Inc., Mimetas B.V., PromoCell GmbH, STEMCELL Technologies Inc., Thermo Fisher Scientific Inc, Tissuse GmbH, and Varian Medical Systems, Inc.

Market Segmentation & Coverage

This research report categorizes the In Vitro Lung Model Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across 2D Models and 3D Models.
  • Based on Application, market is studied across 3D Model Development, Drug Discovery & Toxicology, Physiological Research, and Stem Cell Research & Regenerative Medicine.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing demand for ethical alternatives to animal testing
      • 5.1.1.2. Increase in drug discovery and development
      • 5.1.1.3. Extensive use of in-viro lung model in disease research
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of development and maintainence of in-vitro lung model
    • 5.1.3. Opportunities
      • 5.1.3.1. Inclination toward personalized medicine approach
      • 5.1.3.2. Utilization for toxicity testing of various substances
    • 5.1.4. Challenges
      • 5.1.4.1. Physiological complexity associated with in-vitro lung model
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. In Vitro Lung Model Market, by Type

  • 6.1. Introduction
  • 6.2. 2D Models
  • 6.3. 3D Models

7. In Vitro Lung Model Market, by Application

  • 7.1. Introduction
  • 7.2. 3D Model Development
  • 7.3. Drug Discovery & Toxicology
  • 7.4. Physiological Research
  • 7.5. Stem Cell Research & Regenerative Medicine

8. Americas In Vitro Lung Model Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific In Vitro Lung Model Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa In Vitro Lung Model Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AlveoliX AG
  • 2. Brainlab AG
  • 3. Cn Bio Innovations Limited
  • 4. Emulate, Inc.
  • 5. Epithelix Sarl
  • 6. Hologic, Inc.
  • 7. Horizon Discovery Group plc
  • 8. Insphero AG
  • 9. Lonza Group AG
  • 10. Mattek Corporation by Bico Group
  • 11. McKesson Corporation
  • 12. Merck KGaA
  • 13. MICA Information Systems, Inc.
  • 14. Mimetas B.V.
  • 15. PromoCell GmbH
  • 16. STEMCELL Technologies Inc.
  • 17. Thermo Fisher Scientific Inc
  • 18. Tissuse GmbH
  • 19. Varian Medical Systems, Inc
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦